Tagged with B

France European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both the US and China every year; recent data from ING shows that the percentage of global new drug approvals originating…

France Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path for others to follow.   Amolyt Pharma When AstraZeneca’s rare diseases arm Alexion acquired Lyon-based Amolyt Pharma in a deal…

France Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s most investable life sciences hubs. While less well-known internationally than Basel, Barcelona, London, or Paris, Lyon stands out from the…

Taiwan Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy. Under his leadership, Taiwan Bio advanced MSC and Tregmodalities, built infrastructure via its TDM model, and aims to make immunosuppressants…

Taiwan Taiwan’s clinical research ecosystem has evolved rapidly in recent years, reflecting Asia’s growing role in global drug development. Samuel Su, Founder and CEO of Bestat Pharmaservices, discusses how the organisation has expanded from a data-driven CRO into an integrated development partner supporting preclinical research, multi-regional clinical trials, and international regulatory…

Taiwan Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth drivers, Taiwan’s strategic role in Asia-Pacific, and striking the balance between innovation, digital health, and value-based care. He also shares…

MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…

China Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for the future of access and innovation in the world’s second largest market.   With the tremendous development of China’s innovative…

Global Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World Evidence is providing the definitive proof that prevention is now an economic and medical necessity.   For decades, the guiding…

Taiwan Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for Biotechnology explain how policy, data, manufacturing discipline, and clinical capability are being aligned to create a coherent national ecosystem. The…

USA Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor efficacy through combination therapy, validate science through partnerships with leading institutions, and accelerate timelines to potential regulatory approval. Bedu‑Addo goes…

Hong Kong Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He traces the organisation’s evolution from US-based acquisitions to a protein/peptide and circular RNA vaccine platform built in Hong Kong, explains…